<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1726-8958</journal-id>
<journal-title><![CDATA[Revista Médica La Paz]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. La Paz]]></abbrev-journal-title>
<issn>1726-8958</issn>
<publisher>
<publisher-name><![CDATA[Colegio Médico de La Paz]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1726-89582024000100081</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[INFECCIÓN FÚNGICA INVASORA EN LOS PACIENTES INGRESADOS EN LAS ÁREAS DE CUIDADOS CRÍTICOS]]></article-title>
<article-title xml:lang="en"><![CDATA[INVASIVE FUNGAL INFECTION IN PATIENTS ADMITTED TO CRITICAL CARE AREAS]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Segales Camacho]]></surname>
<given-names><![CDATA[Antonio Ariel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,CNS Hospital Obrero Nro. 1 Servicio de Medicina interna]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>30</volume>
<numero>1</numero>
<fpage>81</fpage>
<lpage>87</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S1726-89582024000100081&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S1726-89582024000100081&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S1726-89582024000100081&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Las infecciones fúngicas invasoras son frecuentes en pacientes inmunosuprimidos y en aquellos ingresados en áreas de cuidados críticos, estas infecciones causan una elevada morbimortalidad. Los hongos son un grupo heterogéneo de microorganismos eucariotas que interaccionan con el ser humano, pueden producir un amplio espectro de situaciones que van desde la erradicación del hongo hasta el fallecimiento de la persona. La especie más frecuente es Candida albicans, presente en la mitad de los casos, la mayoría crecen en forma de levaduras, pero algunas especies pueden formar pseudohifas, con diferentes factores de virulencia, tales como Adhesinas y Proteinasas Aspárticas secretadas, que permiten al microorganismo adherirse tanto a tejidos humanos como a dispositivos protésicos ocasionando injuria tisular y favoreciendo así, la invasión en el sitio de infección respectivamente. Existen muchos factores tales como el uso corticoides, antibióticos, disrupción de barreras naturales además de diversas comorbilidades como la insuficiencia renal crónica, hepatopatía crónica y la pancreatitis aguda necrohemorrágica que contribuyen a la infección. Para su diagnóstico, además de los medios de cultivo convencionales que pueden llevar entre 48 horas o más, actualmente existen nuevas herramientas diagnósticas que pueden reducir el tiempo de diagnóstico a solo pocas horas en los pacientes en quienes se sospecha la infección por Candida sp, entre las más estudiadas están la detección de antígenos fúngicos en sangre, métodos de amplificación de ácidos nucleicos e índices de predicción clínica. El diagnóstico precoz y el oportuno y apropiado tratamiento antifúngico determinan la supervivencia de los pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Invasive fungal infections are common in immunosuppressed patients and in those admitted to critical care areas; these infections cause high morbidity and mortality. Fungi are a heterogeneous group of eukaryotic microorganisms that interact with humans. As a result, a wide spectrum of situations can occur, ranging from eradication of the fungus to death of the person. The most common species is Candida albicans. Most grow in the form of yeast, but some species can form pseudohyphae and produce different virulence factors, such as adhesins and secreted aspartic proteinases. They allow the microorganism to adhere to both human tissues and prosthetic devices in addition to causing tissue injury, thus favoring invasion at the site of infection respectively. Many factors are necessary such as the use of corticosteroids, antibiotics, disruption of natural barriers in addition to various comorbidities such as chronic kidney failure, liver disease, chronic and acute necrohemorrhagic pancreatitis that contribute to infection by this fungus. In addition to conventional culture media that can take 48 hours or more to obtain results, there are currently new diagnostic tools that can reduce the diagnosis time to just a few hours in the patients in whom Candida sp infection is suspected, among the most studied are the detection of fungal antigens in blood, nucleic acid amplification methods and clinical prediction indices. Early diagnosis, timely and appropriate antifungal treatment determine the survival of patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hongo]]></kwd>
<kwd lng="es"><![CDATA[infección]]></kwd>
<kwd lng="es"><![CDATA[cuidados críticos]]></kwd>
<kwd lng="en"><![CDATA[Fungus]]></kwd>
<kwd lng="en"><![CDATA[infection]]></kwd>
<kwd lng="en"><![CDATA[critical care]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Vidal]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Carratala]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patogenia de la infección fúngica invasora]]></article-title>
<source><![CDATA[Enfermedades Infecciosas y Microbiología Clínica]]></source>
<year>2012</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>151-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Mannino]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Eaton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The epidemiology of sepsis in the United States from 1979 through 2000]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>348</volume>
<page-range>1546-54</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bouza]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of candidemia in intensive care units]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2008</year>
<volume>32</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>S87-91</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kett]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Azoulay]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Echeverría]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>2011</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>665-70</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfaller]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Messer]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Moet]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Candida bloodstream infections comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2011</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>65-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="">
<collab>PHO</collab>
<collab>WHO</collab>
<source><![CDATA[Epidemiological alert. Candida auris outbreaks in health care services]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostrosky-Zeichner]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Obaidi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Invasive Fungal Infections in the Intensive Care Unit]]></article-title>
<source><![CDATA[Infect Dis Clin North Am]]></source>
<year>2017</year>
<volume>31</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>475-87</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leroy]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lambiotte]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Thévenin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of &amp;Candida Score&amp; in critically ill patients a prospective, multicenter, observational, cohort study]]></article-title>
<source><![CDATA[Ann Intensive Care]]></source>
<year>2011</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>50</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pappas]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Kauffman]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Andes]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Practice Guideline for the Management of Candidiasis 2016 Update by the Infectious Diseases Society of America]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2016</year>
<volume>62</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e1-50</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Timsit]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Azoulay]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Schwebel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EMPIRICUS Trial Group Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2016</year>
<volume>316</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1555-64</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osthoff]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Khanna]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Siegemund]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The EMPIRICUS trial-the final nail in the coffin of empirical antifungal therapy in the intensive care unit]]></article-title>
<source><![CDATA[J Thorac Dis]]></source>
<year>2017</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>E269-73</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Honore]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Puerta-AJcalde]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Invasive candidiasis current clinical challenges and unmet needs in adult populations]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2023</year>
<volume>78</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1569-85</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
